INDOMETHACIN & SARS-COV-2: PROSPECTS FOR CLINICAL MANAGEMENT OF THE INFLAMMATORY STATE. Review

Abstract

Actuality. Severe acute respiratory syndrome- (SARS) is a pandemic (called as SARS-CoV-2 or COVID-19), severely affected by transmission and fatal disease caused by unknown coronavirus family of RNA virus (SARS-COV). The phenotype can range from asymptomatic to fulminate cytokine storm which leads to multiorgan failure resulting in death. Still, the world is eagerly waiting for antiviral drugs to stop the coronavirus infection. Previous studies found that indomethacin had the ability to inhibit the RNA and DNA virus replication. Objectives. Discuss the possibility of clinical treatment of inflammation caused by SARS-COV-2 with indomethacin. Materials and methods. Analysis of scientific publications in the international electronic scientometric database PubMed by keywords for the period 1991-2020. Comparison with clinical cases. Results. Interleukins, Interferons, and metabolites formed by the enzyme cyclooxygenase (COX 1/COX 2) are active against some RNA viruses. Experts have divided the SARS infection into three phases (phase-1, 2, 3) based on the severity of the infection. In phase-3 there was “cytokine storm” due to exuberant inflammation observed which can damage organs and even fatal. We investigated the effect of indomethacin on the COX inhibitor on coronavirus replication and cytokine storm in reducing the hyperinflammatory state. Indomethacin is a potent inhibitor of SARS CoV-2. Conclusion. Indomethacin can be considered safe and effective for the prevention and treatment of coronavirus infection also antiviral activity.

Keywords

• indomethacin, covid-19,sars-cov 2, inflammation